Yogesh Jethava's guest appearances

Yogesh Jethava

HealthTree Podcast for Multiple Myeloma

Johns Hopkins

Stephen Russell

Adam Cohen

David Siegel

Mike Thompson

Beth Israel

Damian Green

Sarah Cannon

Keith Stewart

Mark Newman

Paul Richardson

Stephen Harding

Kenneth Anderson

Vincent Rajkumar

Thomas Martin

OwlTail

A new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients. Dr. Yogesh Jethava is Associate Professor and Director of the Multiple Myeloma program as well as Associate Director of the Blood and Marrow Program at the University of Iowa. Prior to this appointment, he was director of the Bone Marrow and Stem Cell Transplant Services Division of Hematology Oncology at the Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences or UAMS where he established the first fully functional allo transplant unit. There, he was Director and Attending Physician for the Leukemia and Lymphoma Subspecialty Clinic.  Dr. Jethava is an International Myeloma Working Group member and part of the EMBT malignancy working group and is a member of the Experimental Therapeutics groups and others. He reviews abstracts for publications like blood leukemia in the Blood Cancer Journal, and he is also working on studies that involves high dose vitamin C infusions for plasma cell disorders like myeloma.

A new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients.  Dr. Yogesh Jethava is Associate Professor and Director of the Multiple Myeloma program as well as Associate Director of the Blood and Marrow Program at the University of Iowa. Prior to this appointment, he was director of the Bone Marrow and Stem Cell Transplant Services Division of Hematology Oncology at the Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences or UAMS where he established the first fully functional allo transplant unit. There, he was Director and Attending Physician for the Leukemia and Lymphoma Subspecialty Clinic.   Dr. Jethava is an International Myeloma Working Group member and part of the EMBT malignancy working group and is a member of the Experimental Therapeutics groups and others. He reviews abstracts for publications like blood leukemia in the Blood Cancer Journal, and he is also working on studies that involves high dose vitamin C infusions for plasma cell disorders like myeloma.

Myeloma Crowd Radio: Yogesh Jethava, MD, University of Iowa

Frank Zhan

Targeting CD24 to Eliminate Myeloma Stem CellsMyeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target. Learn more from Dr. Zhan and Dr. Yogesh Jethava of the University of Iowa in this Myeloma Crowd Research Initiative show. Donate to the MCRI here: give.crowdcare.org/mcriThanks to our episode sponsor, Celgene Corporation.

Targeting CD24 to Eliminate Myeloma Stem Cells Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target. Learn more from Dr. Zhan and Dr. Yogesh Jethava of the University of Iowa in this Myeloma Crowd Research Initiative show. Donate to the MCRI here: <a href="http://give.crowdcare.org/mcri" rel="nofollow" target="_blank">give.crowdcare.org/mcri</a> Thanks to our episode sponsor, Celgene Corporation.

Myeloma Crowd Radio: Frank Zhan, PhD and Yogesh Jethava, MD, University of Iowa